Systemic amyloid light chain amyloidosis is a protein conformation disorder caused by a clonal plasma cell dyscrasia. Symptoms result from fibrillar extracellular deposits in kidney, heart, liver, gut, peripheral nervous system and other tissues. The deposits disrupt organ function and ultimately lead to death. The prognosis of systemic amyloid light chain (AL) amyloidosis is poor; less than 5% of all patients survive 10 years or longer. Using conventional chemotherapy, the median survival could be prolonged by 4 months. Treatment with high-dose melphalm (HDM) and autologous stem cell transplantation (ASCT) of selected patients has been shown to arrest and even to reverse the disease course. This procedure however remains controversial because treatment related mortality (TRM) in AL amyloidosis is substantially higher (15-40%) than in multiple myeloma (Ͻ5%). Here we review recent results of ASCT, eligibility criteria for HDM and report our own treatment results in 41 patients.
Indication and Patient Selection for High-dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT)
B ased on the success of ASCT in multiple myeloma (1) some institutions have begun to apply this treatment modality to patients (pts) with amyloid light chain (AL) amyloidosis. Indication for ASCT is systemic disease excluding pts with isolated carpal tunnel syndrome or skin involvement and other localized forms. Table 1 shows the results of singleand multicenter studies (listing only the latest publication from each center). Encouraging hematological remission and organ response rates have been reported. On the other hand treatment-related mortality (TRM) beyond 20% has been observed. Advanced cardiac disease (10, 15), reduced renal function (16) , more than two organs involved (17) , severe hypotension (Ͻ90 mmHg) and poor WHO performance status (8) are risk factors for increased TRM after HDM and ASCT. Therefore patient selection plays a crucial role in the decision for that treatment. The results of the largest patient group have been reported by Skinner et al. (10). Out of 701 patients with AL amyloidosis, 394 were considered eligible for HDM and ASCT. In this group, 82 patients did not proceed to HDM because of their own decision or disease progression. The median survival of 312 patients treated with HDM was 4.6 years. A hematological complete remission (CR) was achieved in 40% of pts evaluable at one year after ASCT, and was associated with prolonged survival. Significantly higher organ response rates were observed in these pts (66% vs. 30% in CR vs. non-CR, PϽ0.001). The disappearance of the monoclonal plasma cells after HDM is correlated with melphalan dosage used. Risk factor for TRM was symptomatic cardiac involvement. Survival, CR rate, and organ function improvement were higher for transplanted pts compared to the results of any other therapy. Pretreatment with 2 cycles of oral melphalan/prednisone before transplantation did not improve results in a prospective randomized trial (18) . Furthermore, superior survival in pts undergoing HDM and ASCT was observed in a case-control study reported by the Mayo Group (19) . Sixty-three patient pairs had been matched for age, sex, time to clinical presentation, left ventricular ejection fraction, serum creatinine, septum thickness, nerve in-volvement, 24-hour urine protein excretion, and serum alkaline phosphatase. Sixteen pts treated with HDM and 50 control pts died. Comparing the HDM and the control group, the 1-, 2-, and 4-year overall surivival (OS) rates were significantly different (89% and 71%; 81% and 55%; and 71% and 41%; PϽ0,001). These results underline the importance of high-dose therapy in the treatment of AL amyloidosis. On the other hand, eligibility for HDM is a favorable prognostic factor for OS of pts not undergoing HDM (20) . To further evaluate the role of ASCT, a French prospective randomised clinical phase III study comparing melphalan-dexamethasone with HDM is under way, but has not been finished yet (21) .
A number of different risk-adapted approaches to assess eligibility for HDM and ASCT have been published recently. In one report (17) , patients were classified in three risk groups (good-intermediate-poor). Good-risk pts could be of any age, had 1 or 2 organs involved, no signs of cardiac disease and a creatinine clearance Ն 51 ml/min. Intermediate risk pts were younger than 71 years, had 1 or 2 organs involved (either cardiac disease or creatinine clearance Յ 51 ml/min) and only asymptomatic or compensated heart disease. Poor risk pts had more than 2 organs involved or advanced cardiac disease. In this approach melphalan dosages were based on the risk group and age. For poor risk pts HDM and ASCT was not recommended. The Boston Group algorithm (10) included pts up to the age of 80 y. Pts were ineligible for HDM if they had decompensated congestive heart failure, cardiac ejection fraction Ͻ40%, persistent pleural effusions, systolic blood pressure Յ90 mm Hg, O 2 saturation Ͻ95% by room air or a performance status Ն3. The melphalan dosage depended on age, cardiac ejection fraction and number of collected stem cells. The British Guidelines for diagnosis and management of AL amyloidosis (22) recommended HDM and ASCT only for good-risk pts (17) who are refractory or relapsed after initial therapy. The Italian GITMO transplants pts younger than 60 y, with no more than 2 organs involved and without severe heart involvement (23). At our institution exclusion criteria for HDM and ASCT are age beyond 70 y, symptomatic heart involvement with NYHA stage III or IV and WHO performance status Ͼ2 (3 if due to PNP).
Own Treatment Results
We have treated 41 pts with HDM and ASCT between 1998 and 2004. Thirty-seven pts had AL amyloidosis and 4 pts multiple myeloma stage III with AL amyloidosis. Patient characteristics are summarized in Table 2 . All pts had received mobilization chemotherapy and 40 out of 41 have been pretreated with VAD, dexamethasone or melphalan/prednisone (Table 2 and (9)). Melphalan dosage was adapted to creatinine clearance and was reduced in pts older than 65 y or with symptomatic cardiac disease. CR was obtained in 16 out of 32 (50%) and organ response was observed in 15 out of 37 pts evaluable (40%). In further 18 pts organ function was stabilized (49%). Thirty-seven out of 41 pts are alive after a median observation of 24 months since HDM. The TRM was 7%. However, this rather low rate is not a result of a very restrictive patient selection ( Table 2) . One patient died of cardiac failure due to AL amyloidosis 8 months after ASCT. The OS rate at 2 y is 89% (Fig. 1) . Currently we investigate the toxicity and efficacy of pulsed high-dose dexamethasone as induction therapy prior to HDM and ASCT in a phase II study.
Summary
HDM is currently the treatment of choice for pts who are eligible to undergo this treatment. Long-term survival has been significantly improved for pts who achieve a CR after HDM. Supportive therapy of cardiac and renal disease plays a substantial role in the treatment of these pts. Providing a network of different medical specialists with expertise in the field of AL amyloidosis within the same centre is important for the optimal care for these pts and may lead to a further reduction of TRM. Treatment of pts who are not eligible for high-dose chemotherapy and of pts with persistent or relapsed clonal disease after transplantation is still a challenge. For these pts new drugs (bortezomib, lenalidomide) have to be tested in clinical studies. 
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